EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment
Protein tyrosine kinases of the human epidermal growth factor receptor family, including
EGFR and HER2, have emerged as important therapeutic targets in non-small-cell lung …
EGFR and HER2, have emerged as important therapeutic targets in non-small-cell lung …
Precision therapy for RET-altered cancers with RET inhibitors
Rearranged during transfection (RET) is involved in the physiological development of some
organ systems. Activating RET alterations via either gene fusions or point mutations are …
organ systems. Activating RET alterations via either gene fusions or point mutations are …
Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer
YL Wu, R Dziadziuszko, JS Ahn, F Barlesi… - … England Journal of …, 2024 - Mass Medical Soc
Background Platinum-based chemotherapy is the recommended adjuvant treatment for
patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC). Data on the …
patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC). Data on the …
[HTML][HTML] Novel targets for immune-checkpoint inhibition in cancer
Immune-checkpoint inhibitors have revolutionized cancer therapy, yet many patients either
do not derive any benefit from treatment or develop a resistance to checkpoint inhibitors …
do not derive any benefit from treatment or develop a resistance to checkpoint inhibitors …
Deciphering the tumor immune microenvironment from a multidimensional omics perspective: insight into next-generation CAR-T cell immunotherapy and beyond
Z Zhou, J Wang, J Wang, S Yang, R Wang, G Zhang… - Molecular Cancer, 2024 - Springer
Tumor immune microenvironment (TIME) consists of intra-tumor immunological components
and plays a significant role in tumor initiation, progression, metastasis, and response to …
and plays a significant role in tumor initiation, progression, metastasis, and response to …
Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer
As advanced non-small cell lung cancer (aNSCLC) is being increasingly divided into rare
oncogene-driven subsets, conducting randomised trials becomes challenging. Using real …
oncogene-driven subsets, conducting randomised trials becomes challenging. Using real …
New promises and challenges in the treatment of advanced non-small-cell lung cancer
ML Meyer, BG Fitzgerald, L Paz-Ares, F Cappuzzo… - The Lancet, 2024 - thelancet.com
Targeted therapies and immunotherapies have radically improved treatment for advanced
non-small-cell lung cancer (NSCLC). Tyrosine kinase inhibitors targeting oncogenic driver …
non-small-cell lung cancer (NSCLC). Tyrosine kinase inhibitors targeting oncogenic driver …
RET aberrant cancers and RET inhibitor therapies: current state-of-the-art and future perspectives
Precision oncology informed by genomic information has evolved in leaps and bounds over
the last decade. Although non-small cell lung cancer (NSCLC) has moved to center-stage as …
the last decade. Although non-small cell lung cancer (NSCLC) has moved to center-stage as …
Exosome nanovesicles as potential biomarkers and immune checkpoint signaling modulators in lung cancer microenvironment: recent advances and emerging …
Lung cancer remains the leading cause of cancer-related deaths globally, and the survival
rate remains low despite advances in diagnosis and treatment. The progression of lung …
rate remains low despite advances in diagnosis and treatment. The progression of lung …
[HTML][HTML] Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single …
X Chen, X Xu, D Wang, J Liu, J Sun, M Lu… - … for ImmunoTherapy of …, 2023 - ncbi.nlm.nih.gov
Background The standard neoadjuvant treatments in patients with esophageal squamous
cell carcinoma (ESCC) still have either poor safety or efficacy. Better therapies are needed …
cell carcinoma (ESCC) still have either poor safety or efficacy. Better therapies are needed …